ÂÜÀòÂÒÂ×

Daniella Beckman is the current Director at Blueprint Medicines. Prior to this, they were the Board Member and Audit Committee Chair at Translate Bio from October 2017 to September 2021. From November 2015 to September 2019, they were the CFO at Beckman Consulting LLC where they were part-time CFO for biotech companies in the Boston area, including Tango Therapeutics. Daniella mainly focused on building financial infrastructure and leading financial functions, including strategic financial planning and aiding with securing Series B financing. Prior to that, they were the CFO at Idenix Pharmaceuticals from March 2008 to September 2014 and Corporate Controller at Coley Pharmaceutical, Inc from March 2006 to February 2008. Daniella started their career as a Senior Financial Analyst at Biogen Idec, Inc from September 2004 to February 2006 and later became a Senior Associate, Audit at PricewaterhouseCoopers from September 2000 to August 2004.

Daniella Beckman has a Bachelor's degree in Accounting from the Questrom School of Business at Boston University.